SynthesisFrontiers in nutrition2026
Prevalence of fatty pancreas and its associations with pancreatic disease and metabolic disorders: a systematic review and meta-analysis of 124 studies.
Synthesis in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prevalence and impact of fatty pancreas (FP) on pancreatic and metabolic disorders remain incompletely characterized. We synthesized current evidence on FP prevalence and its associations with pancreatic and metabolic disorders. Methods: We performed a systematic review and meta-analysis of PubMed, Embase, and Cochrane Library through October 22, 2024. Prevalence was analyzed separately in the healthy population and the overall study population, with restricted sensitivity analyses according to population selection. Results: From 3,984 records, 124 studies were included. The pooled prevalence was 30.5% among 141,416 healthy or routine-examination participants and 42.3% across all included study populations. After pancreatic disease, pancreatic surgical, and metabolic high-risk populations were excluded, the prevalence was 31.1%. In the healthy population, FP prevalence varied by region, ranging from 12.0% in Africa to 38.8% in the Region of the Americas, although estimates for some regions were based on limited country-level data. Higher prevalence was observed in older age, male sex, high-income countries, and very-high-HDI regions. FP prevalence was higher in 2020-2024 than in the preceding publication period in both the overall study population and the healthy population, while temporal meta-regression showed positive but non-significant slopes. FP was associated with increased risks of pancreatitis (OR 2.66), pancreatic cancer (OR 3.01), fatty liver (OR 4.86), metabolic syndrome (OR 3.90), obesity (OR 2.75), diabetes mellitus (OR 2.43), and hypertension (OR 2.17; all Conclusion: FP was common in the included populations and was associated with several pancreatic and metabolic disorders. Prevalence was higher in recent publication periods, although continuous temporal trends were not statistically significant. These findings support greater clinical attention to FP, particularly among older adults and high-risk populations. Targeted evaluation for associated disorders and appropriate risk-factor management may be considered in individuals with FP. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024499559, CRD42024499559.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.